<?xml version='1.0' encoding='utf-8'?>
<document id="20413453"><sentence text="Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants."><entity charOffset="10-19" id="DDI-PubMed.20413453.s1.e0" text="verapamil" /><entity charOffset="47-56" id="DDI-PubMed.20413453.s1.e1" text="aliskiren" /><pair ddi="false" e1="DDI-PubMed.20413453.s1.e0" e2="DDI-PubMed.20413453.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20413453.s1.e0" e2="DDI-PubMed.20413453.s1.e1" /></sentence><sentence text="The authors describe the drug-drug interaction between aliskiren and verapamil in healthy participants"><entity charOffset="55-64" id="DDI-PubMed.20413453.s2.e0" text="aliskiren" /><entity charOffset="69-78" id="DDI-PubMed.20413453.s2.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.20413453.s2.e0" e2="DDI-PubMed.20413453.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20413453.s2.e0" e2="DDI-PubMed.20413453.s2.e1" /></sentence><sentence text=" Eighteen participants first received an oral dose of aliskiren 300 mg (highest recommended clinical dose) in period 1"><entity charOffset="54-63" id="DDI-PubMed.20413453.s3.e0" text="aliskiren" /></sentence><sentence text=" After a 10-day washout period, the participants received verapamil 240 mg/d for 8 days (period 2)" /><sentence text=" On day 8, the participants also received an oral dose of aliskiren 300 mg"><entity charOffset="58-67" id="DDI-PubMed.20413453.s5.e0" text="aliskiren" /></sentence><sentence text=" Safety and pharmacokinetic analyses were performed during each treatment period" /><sentence text=" Concomitant administration of a single dose of aliskiren during steady-state verapamil resulted in an increase in plasma concentration of aliskiren"><entity charOffset="48-57" id="DDI-PubMed.20413453.s7.e0" text="aliskiren" /><entity charOffset="139-148" id="DDI-PubMed.20413453.s7.e1" text="aliskiren" /><pair ddi="false" e1="DDI-PubMed.20413453.s7.e0" e2="DDI-PubMed.20413453.s7.e0" /><pair ddi="false" e1="DDI-PubMed.20413453.s7.e0" e2="DDI-PubMed.20413453.s7.e1" /></sentence><sentence text=" The mean increase in AUC(0-∞), AUC(last), and C(max) was about 2-fold" /><sentence text=" On day 8, in the presence of aliskiren, AUC(τ,ss) of R-norverapamil, R-verapamil, S-norverapamil, and S-verapamil was decreased by 10%, 16%, 10%, and 25%, respectively"><entity charOffset="30-39" id="DDI-PubMed.20413453.s9.e0" text="aliskiren" /><entity charOffset="54-68" id="DDI-PubMed.20413453.s9.e1" text="R-norverapamil" /><entity charOffset="70-81" id="DDI-PubMed.20413453.s9.e2" text="R-verapamil" /><entity charOffset="83-97" id="DDI-PubMed.20413453.s9.e3" text="S-norverapamil" /><entity charOffset="103-114" id="DDI-PubMed.20413453.s9.e4" text="S-verapamil" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e0" e2="DDI-PubMed.20413453.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e0" e2="DDI-PubMed.20413453.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e0" e2="DDI-PubMed.20413453.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e0" e2="DDI-PubMed.20413453.s9.e3" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e0" e2="DDI-PubMed.20413453.s9.e4" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e1" e2="DDI-PubMed.20413453.s9.e1" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e1" e2="DDI-PubMed.20413453.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e1" e2="DDI-PubMed.20413453.s9.e3" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e1" e2="DDI-PubMed.20413453.s9.e4" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e2" e2="DDI-PubMed.20413453.s9.e2" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e2" e2="DDI-PubMed.20413453.s9.e3" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e2" e2="DDI-PubMed.20413453.s9.e4" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e3" e2="DDI-PubMed.20413453.s9.e3" /><pair ddi="false" e1="DDI-PubMed.20413453.s9.e3" e2="DDI-PubMed.20413453.s9.e4" /></sentence><sentence text=" Similarly, the C(max,ss) of R-norverapamil, R-verapamil, S-norverapamil, and S-verapamil was decreased by 13%, 18%, 12%, and 24%, respectively"><entity charOffset="29-43" id="DDI-PubMed.20413453.s10.e0" text="R-norverapamil" /><entity charOffset="45-56" id="DDI-PubMed.20413453.s10.e1" text="R-verapamil" /><entity charOffset="58-72" id="DDI-PubMed.20413453.s10.e2" text="S-norverapamil" /><entity charOffset="78-89" id="DDI-PubMed.20413453.s10.e3" text="S-verapamil" /><pair ddi="false" e1="DDI-PubMed.20413453.s10.e0" e2="DDI-PubMed.20413453.s10.e0" /><pair ddi="false" e1="DDI-PubMed.20413453.s10.e0" e2="DDI-PubMed.20413453.s10.e1" /><pair ddi="false" e1="DDI-PubMed.20413453.s10.e0" e2="DDI-PubMed.20413453.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20413453.s10.e0" e2="DDI-PubMed.20413453.s10.e3" /><pair ddi="false" e1="DDI-PubMed.20413453.s10.e1" e2="DDI-PubMed.20413453.s10.e1" /><pair ddi="false" e1="DDI-PubMed.20413453.s10.e1" e2="DDI-PubMed.20413453.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20413453.s10.e1" e2="DDI-PubMed.20413453.s10.e3" /><pair ddi="false" e1="DDI-PubMed.20413453.s10.e2" e2="DDI-PubMed.20413453.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20413453.s10.e2" e2="DDI-PubMed.20413453.s10.e3" /></sentence><sentence text=" Aliskiren did not affect the AUC(τ,ss) ratios of R-norverapamil/R-verapamil and S-norverapamil/S-verapamil"><entity charOffset="1-10" id="DDI-PubMed.20413453.s11.e0" text="Aliskiren" /><entity charOffset="50-64" id="DDI-PubMed.20413453.s11.e1" text="R-norverapamil" /><entity charOffset="81-95" id="DDI-PubMed.20413453.s11.e2" text="S-norverapamil" /><entity charOffset="96-107" id="DDI-PubMed.20413453.s11.e3" text="S-verapamil" /><pair ddi="false" e1="DDI-PubMed.20413453.s11.e0" e2="DDI-PubMed.20413453.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20413453.s11.e0" e2="DDI-PubMed.20413453.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20413453.s11.e0" e2="DDI-PubMed.20413453.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20413453.s11.e0" e2="DDI-PubMed.20413453.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20413453.s11.e1" e2="DDI-PubMed.20413453.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20413453.s11.e1" e2="DDI-PubMed.20413453.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20413453.s11.e1" e2="DDI-PubMed.20413453.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20413453.s11.e2" e2="DDI-PubMed.20413453.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20413453.s11.e2" e2="DDI-PubMed.20413453.s11.e3" /></sentence><sentence text=" Aliskiren administered alone or in combination with verapamil was well tolerated in healthy participants"><entity charOffset="1-10" id="DDI-PubMed.20413453.s12.e0" text="Aliskiren" /><entity charOffset="53-62" id="DDI-PubMed.20413453.s12.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.20413453.s12.e0" e2="DDI-PubMed.20413453.s12.e0" /><pair ddi="false" e1="DDI-PubMed.20413453.s12.e0" e2="DDI-PubMed.20413453.s12.e1" /></sentence><sentence text=" In conclusion, no dose adjustment is necessary when aliskiren is administered with moderate ABCB1 inhibitors such as verapamil (240 mg/d)"><entity charOffset="53-62" id="DDI-PubMed.20413453.s13.e0" text="aliskiren" /><entity charOffset="118-127" id="DDI-PubMed.20413453.s13.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.20413453.s13.e0" e2="DDI-PubMed.20413453.s13.e0" /><pair ddi="false" e1="DDI-PubMed.20413453.s13.e0" e2="DDI-PubMed.20413453.s13.e1" /></sentence><sentence text="" /></document>